hrp0089rfc6.2 | Fat, Metabolism and Obesity | ESPE2018

IGF-I at Four Months Associates to Visceral and Subcutaneous Adipose Tissue at 7 Years of Age

Kjellberg Emma , Roswall Josefine , Andersson Jonathan , Bergman Stefan , Kullberg Joel , Dahlgren Jovanna

Objectives and Study: Insulin-like growth factor I (IGF-I) regulates fetal and infant growth and is influenced by nutrition during infancy. Breast fed children have lower IGF-I levels than formula fed infants and the reason is partly explained by lower levels of protein and higher level of polyunsaturated fatty acids (PUFA) in breast milk compared to formula. Environmental factors, such as nutrition, have long-lasting influences on hormone secretion and on future metabolic hea...

hrp0089p2-p218 | GH & IGFs P2 | ESPE2018

The Rationale and Design of TransCon GH

Sprogoe Kennett , Beckert Michael , Mortensen Eva , Karpf David B , Leff Jonathan A

Background: The fundamental challenge of developing a long-acting growth hormone (LAGH) is to create a more convenient growth hormone (GH) dosing profile while retaining the excellent safety, efficacy, and tolerability of daily GH. With GH receptors on virtually all cells, replacement therapy should achieve the same tissue distribution and effects of daily (and endogenous) GH while maintaining levels of GH and resulting IGF1 within the physiologic range....

hrp0089p2-p219 | GH & IGFs P2 | ESPE2018

Baseline Demographics of the TransCon GH Phase 3 heiGHt Trial

Beckert Michael , Karpf David B , Shu Aimee , Lin Zhengning , Leff Jonathan A

Background: TransCon GH is a novel sustained-release recombinant human GH (somatropin) prodrug in development for children with GH deficiency (GHD). It is designed to release unmodified GH and intended to provide comparable efficacy, safety, tolerability, and immunogenicity to daily GH with once-weekly dosing. Based on results from a phase 2 trial, which demonstrated comparable efficacy (annualized height velocity for TransCon 0.21 mg GH/kg per week of 12.9 cm/year vs 11.6 cm/...

hrp0086p1-p200 | Diabetes P1 | ESPE2016

Driving Paediatric Diabetes Care Forward in the UK: Improvements in Outcomes in the North West Following National Initiatives

Moore Helen S , Carson Margot E , Maiden Jonathan , Ng Sze May

Background: Type 1 diabetes mellitus (T1DM) continues to pose serious health risks with devastating long-term complications. UK management and control of T1DM in children and young people (CYP) remains amongst the poorest in Europe and significant variations in diabetes health outcomes are evident. In 2012–13 a Best Practice Tariff (BPT) for paediatric diabetes care was introduced and a National Peer Review Quality Assurance programme (DQuINS) developed. Both were develop...

hrp0082p1-d3-18 | Adrenals & HP Axis (1) | ESPE2014

Zenhale Inhaled Corticosteroid Therapy: Useful Second Line Therapy for Asthma in Children but be Wary of Adrenal Suppression

Perry Rebecca , Schwarz Wendy , Stosky Karen , Dawrant Jonathan , Pacaud Daniele , Noseworthy Mary , Anselmo Mark

Background: Children with Asthma who do not respond to first-line therapy may need inhaled corticosteroid-long-acting beta agonist combination (ICS-LABA) therapy. Adrenal insufficiency (AI) due to adrenal suppression is a recognized but relatively uncommon side effect of ICS. An increase in suspected cases of AI associated with one particular ICS-LABA, mometasone-formoterol (Zenhale) was observed at a tertiary care Asthma clinic over a 6-month period.Obj...

hrp0094p1-191 | Thyroid B | ESPE2021

The Impact of Hospital Surgical Volume on Healthcare Utilisation Outcomes after Paediatric Thyroidectomy

Chesover Alexander , Eskander Antoine , Griffiths Rebecca , Pasternak Jesse , Pole Jason , Wolter Nikolaus , Wasserman Jonathan ,

Background: A positive relationship between an individual surgeon’s operative volume and clinical outcomes after paediatric and adult thyroidectomy is well-established. The impact of a hospital’s paediatric operative volume on surgical outcomes and healthcare utilisation, however, are infrequently reported. We investigated associations between hospital volume and healthcare utilisation outcomes following paediatric thyroidectomy in Canada’s larg...

hrp0097p1-91 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Short- and Long-term Outcomes of Diazoxide Unresponsive Infants with Diffuse Hyperinsulinism

Rafferty Deborah , Truong Lisa , Nedrelow Jonathan , Uffman Chip , Pugenent Burton , Sanchez Irene , Thornton Paul

Background: Severe diazoxide unresponsive hyperinsulinism (DUHI) is most often caused by autosomal recessive variants in the KATP channel genes. Because of the limited medical treatments available, many patients are treated with 98% pancreatectomy. This results in a high rate of diabetes by the age of 15 years. Many centers now try to avoid surgery to prevent the inevitable transition to post-surgical diabetes.Objectives:</strong...

hrp0089p2-p160 | Fat, Metabolism and Obesity P2 | ESPE2018

Obesogenic Environment and Their Influence on Adiposity on Mexican Children and Adolescents

Lopez-Gonzalez Desiree , Wells Jonathan , Reyes-Delpech Pamela , Avila-Rosano Fatima , Ortiz-Obregon Marcela , Gomez-Mendoza Frida , Clark Patricia

Introduction: Obesity is the main public health problem in Mexico. Several factors have been described as explanations, mainly: increased sedentarism and caloric intake. Such environment has been described as “obesogenic”. The aim of this study was to describe the relationship between the components of such obesogenic environment and the adiposity of Mexican children and adolescents.Methods: We carried a population-based cross-sectional study o...

hrp0089p2-p342 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P2 | ESPE2018

In-silico Gene-protein Analysis and Clinical Phenotype Characterisation of Three Novel NR5A1/SF1 Gene Mutations Presenting with 46,XY DSD

Cuccaro Rieko Tadokoro , Thankamony Ajay , Hendriks A Emile J , Alvi Sabah , Armstrong Ruth , Bruty Jonathan , A Hughes Ieuan , L Acerini Carlo

Background: Disorders of sex development (DSD) due to mutations in the NR5A1 (SF1) gene result in a highly variable phenotype.Objective: To report the clinical phenotype and the molecular/structural characteristics of the gene-protein product arising from three novel mutations of the NR5A1 (SF1) gene found in patients presenting with 46,XY DSD.Method: Phenotype determined from interrogation of clinical case notes. Interpre...

hrp0084p1-28 | Diabetes | ESPE2015

Clinical Characterisation of a Novel RFX6 Mutation – A Rare Cause of Neonatal Diabetes Syndrome

Cheung Moira , Chapman Simon , Hunt Katie , Makin Erin , Hickey Ann , Hind Jonathan , Ellard Sian , Buchanan Charles , Kapoor Ritika

Background: Mitchell Riley syndrome is a rare syndrome caused by mutations in the RFX6 gene, resulting in neonatal diabetes, intestinal atresia, pancreatic abnormalities, and biliary hypoplasia. RFX6 is a winged helix transcription factor that is expressed in the developing pancreas and in the gut endoderm. Previous eight case reports highlight poor outcomes with usually a fatal course in infancy.Case presentation: Twin 2 of a dichorion...